Patient characteristics and treatment
From October 2017 to September 2021, a total of 116 patients met the inclusion criteria, of which eight patients were excluded. Finally, 108 patients were randomly assigned to the FOLFOX4-ATRA group (Flow diagram of patient disposition. ATRA all-trans retinoic acid, FOLFOX4 infusional fluorouracil, leucovorin, and oxaliplatinBaseline patient demographics and clinical characteristics in ITT population (